Saika M et al. |
17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. |
2001 |
Endocrinology |
pmid:11356664
|
Mackie PS et al. |
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. |
2001 |
Br. J. Cancer |
pmid:11286476
|
Hofbauer LC et al. |
Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. |
2001 |
J. Rheumatol. |
pmid:11327234
|
Hofbauer LC and Heufelder AE |
The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. |
2001 |
Arthritis Rheum. |
pmid:11229454
|
Leach RJ et al. |
The genetics of Paget's disease of the bone. |
2001 |
J. Clin. Endocrinol. Metab. |
pmid:11231972
|
Luger NM et al. |
Osteoprotegerin diminishes advanced bone cancer pain. |
2001 |
Cancer Res. |
pmid:11358823
|
Haynes DR et al. |
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. |
2001 |
Rheumatology (Oxford) |
pmid:11426018
|
Szulc P et al. |
Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. |
2001 |
J. Clin. Endocrinol. Metab. |
pmid:11443182
|
Sakiyama H et al. |
Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. |
2001 |
J. Bone Miner. Metab. |
pmid:11448014
|
Choi Y et al. |
Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. |
2001 |
Eur. J. Immunol. |
pmid:11449372
|
Goltzman D |
Osteolysis and cancer. |
2001 |
J. Clin. Invest. |
pmid:11375409
|
Zhang J et al. |
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. |
2001 |
J. Clin. Invest. |
pmid:11375413
|
Kostenuik PJ and Shalhoub V |
Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. |
2001 |
Curr. Pharm. Des. |
pmid:11375772
|
Thirunavukkarasu K et al. |
Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. |
2001 |
J. Biol. Chem. |
pmid:11451955
|
Yun TJ et al. |
Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. |
2001 |
J. Immunol. |
pmid:11160187
|
Stejskal D et al. |
Osteoprotegerin, RANK, RANKL. |
2001 |
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub |
pmid:12426773
|
Stejskal D et al. |
Osteoprotegerin and bone density. |
2001 |
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub |
pmid:12426776
|
Takeuchi T et al. |
Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. |
2001 |
Biochem. Pharmacol. |
pmid:11239501
|
Mori K et al. |
Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. |
2001 |
Cell. Immunol. |
pmid:11243701
|
Hofbauer LC et al. |
Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. |
2001 |
Biochem. Biophys. Res. Commun. |
pmid:11162519
|
Brändström H et al. |
Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. |
2001 |
Biochem. Biophys. Res. Commun. |
pmid:11162596
|
Wuyts W et al. |
Evaluation of the role of RANK and OPG genes in Paget's disease of bone. |
2001 |
Bone |
pmid:11165949
|
Michigami T et al. |
Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. |
2001 |
Cancer Res. |
pmid:11245477
|
Wada N et al. |
Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. |
2001 |
J. Periodont. Res. |
pmid:11246705
|
Jung K et al. |
Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. |
2001 |
Clin. Chem. |
pmid:11673385
|
Lean JM et al. |
FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. |
2001 |
Blood |
pmid:11675341
|
Fiumara P et al. |
Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. |
2001 |
Blood |
pmid:11675352
|
Satoh K et al. |
Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. |
2001 |
Pancreas |
pmid:11590320
|
Yano K et al. |
Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy. |
2001 |
Biochem. Biophys. Res. Commun. |
pmid:11594776
|
Brown JM et al. |
Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. |
2001 |
Clin. Cancer Res. |
pmid:11595685
|
Price PA et al. |
Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. |
2001 |
Arterioscler. Thromb. Vasc. Biol. |
pmid:11597934
|
Nemec K and Schubert-Zsilavecz M |
[Future therapies for metabolic bone diseases. New concepts and targets]. |
2001 |
Pharm Unserer Zeit |
pmid:11715689
|
Kuntz KA et al. |
An immunohistochemical study of osteoprotegerin in the human dental pulp. |
2001 |
J Endod |
pmid:11716077
|
Hofbauer LC and Schoppet M |
Serum measurement of osteoprotegerin--clinical relevance and potential applications. |
2001 |
Eur. J. Endocrinol. |
pmid:11720890
|
Ueland T et al. |
Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. |
2001 |
Eur. J. Endocrinol. |
pmid:11720891
|
Pearse RN et al. |
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. |
2001 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:11562486
|
Kostenuik PJ et al. |
OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. |
2001 |
Endocrinology |
pmid:11564687
|
Marco-Mingot M et al. |
Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. |
2001 |
Clin. Genet. |
pmid:11531977
|
Raffai RL et al. |
Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. |
2001 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:11553788
|
Hocking LJ et al. |
Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. |
2001 |
Am. J. Hum. Genet. |
pmid:11555792
|
Hofbauer LC et al. |
Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. |
2001 |
Cancer |
pmid:11505389
|
Hofbauer LC and Heufelder AE |
Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. |
2001 |
J. Mol. Med. |
pmid:11485016
|
Furuya D et al. |
Immuno-PCR assay for homodimeric osteoprotegerin. |
2001 |
Clin. Chem. |
pmid:11468243
|
Seck T et al. |
Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. |
2001 |
Eur. J. Endocrinol. |
pmid:11454517
|
Burguera B et al. |
Leptin reduces ovariectomy-induced bone loss in rats. |
2001 |
Endocrinology |
pmid:11459801
|
Yamagishi T et al. |
Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. |
2001 |
Endocrinology |
pmid:11459812
|
Ma YL et al. |
Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. |
2001 |
Endocrinology |
pmid:11517184
|
Bateman TA et al. |
Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. |
2001 |
J. Orthop. Res. |
pmid:11518255
|
Myoung H et al. |
Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. |
2001 |
J. Periodont. Res. |
pmid:11519698
|
Haynes DR et al. |
The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. |
2001 |
J Bone Joint Surg Br |
pmid:11521937
|
Hofbauer LC and Schoppet M |
Osteoprotegerin: a link between osteoporosis and arterial calcification? |
2001 |
Lancet |
pmid:11498208
|
Sakai A et al. |
1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. |
2001 |
J. Bone Miner. Metab. |
pmid:11498729
|
Ikeda T et al. |
Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. |
2001 |
J. Bone Miner. Res. |
pmid:11499864
|
Thomas GP et al. |
Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. |
2001 |
J. Endocrinol. |
pmid:11479141
|
Allan GF et al. |
Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. |
2001 |
Steroids |
pmid:11546554
|
Halladay DL et al. |
Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. |
2001 |
J. Cell. Biochem. |
pmid:11746511
|
Cao Y et al. |
IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. |
2001 |
Cell |
pmid:11747812
|
Chung H et al. |
Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. |
2001 |
J. Korean Med. Sci. |
pmid:11748360
|
Komuro H et al. |
The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. |
2001 |
Arthritis Rheum. |
pmid:11762937
|
Lindberg MK et al. |
Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. |
2001 |
J. Endocrinol. |
pmid:11739008
|
Giuliani N et al. |
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. |
2001 |
Blood |
pmid:11739153
|
Croucher PI et al. |
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. |
2001 |
Blood |
pmid:11739154
|
Dhore CR et al. |
Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. |
2001 |
Arterioscler. Thromb. Vasc. Biol. |
pmid:11742876
|
Ramalho AC et al. |
Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. |
2001 |
Cytokine |
pmid:11792122
|
Horowitz MC et al. |
Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. |
2001 |
Cytokine Growth Factor Rev. |
pmid:11312114
|
Lin DL et al. |
Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. |
2001 |
Prostate |
pmid:11351351
|
Sparks AB et al. |
Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. |
2001 |
Calcif. Tissue Int. |
pmid:11351498
|
Disthabanchong S and González EA |
Regulation of bone cell development and function: implication for renal osteodystrophy. |
2001 |
J. Investig. Med. |
pmid:11352181
|
Kotake S et al. |
Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. |
2001 |
Arthritis Rheum. |
pmid:11352231
|
Yan T et al. |
Regulation of osteoclastogenesis and RANK expression by TGF-beta1. |
2001 Aug 1-9 |
J. Cell. Biochem. |
pmid:11573248
|
Rosa-Rañal M et al. |
[New paradigms in the regulation of bone metabolism]. |
2001 Jul-Aug |
Rev. Invest. Clin. |
pmid:11599485
|
Lorget F et al. |
Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. |
2002 |
Biochem. Biophys. Res. Commun. |
pmid:12163011
|
Ulrich-Vinther M et al. |
Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. |
2002 |
J Bone Joint Surg Am |
pmid:12177271
|
Ohmori H et al. |
Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. |
2002 |
J. Hum. Genet. |
pmid:12181640
|
Armstrong AP et al. |
A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. |
2002 |
J. Biol. Chem. |
pmid:12185073
|
Schoppet M et al. |
RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. |
2002 |
Arterioscler. Thromb. Vasc. Biol. |
pmid:11950689
|
Hasegawa T et al. |
Human periodontal ligament cells derived from deciduous teeth induce osteoclastogenesis in vitro. |
2002 |
Tissue Cell |
pmid:11989970
|
Langdahl BL et al. |
Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. |
2002 |
J. Bone Miner. Res. |
pmid:12096838
|
Zhang J et al. |
Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. |
2002 |
J. Bone Miner. Res. |
pmid:12096839
|
Treuheit MJ et al. |
Inverse relationship of protein concentration and aggregation. |
2002 |
Pharm. Res. |
pmid:12033388
|
Lossdörfer S et al. |
Immunohistochemical localization of receptor activator of nuclear factor kappaB (RANK) and its ligand (RANKL) in human deciduous teeth. |
2002 |
Calcif. Tissue Int. |
pmid:12043011
|
Wynne F et al. |
Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. |
2002 |
Calcif. Tissue Int. |
pmid:12073153
|
Crotti TN et al. |
Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. |
2002 |
Ann. Rheum. Dis. |
pmid:12429533
|
Hofbauer LC and Schoppet M |
Osteoprotegerin deficiency and juvenile Paget's disease. |
2002 |
N. Engl. J. Med. |
pmid:12432053
|
Jono S et al. |
Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. |
2002 |
Circulation |
pmid:12208791
|
Sedger LM et al. |
Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. |
2002 |
Eur. J. Immunol. |
pmid:12209637
|
Hofbauer LC et al. |
Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. |
2002 |
J. Cell. Biochem. |
pmid:12210731
|
Kondo H et al. |
Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. |
2002 |
J. Bone Miner. Res. |
pmid:12211438
|
Stajszczyk M |
[Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism]. |
2002 |
Pol. Arch. Med. Wewn. |
pmid:12600190
|
Fahrleitner A et al. |
Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. |
2002 |
Wien. Klin. Wochenschr. |
pmid:12602117
|
Theill LE et al. |
RANK-L and RANK: T cells, bone loss, and mammalian evolution. |
2002 |
Annu. Rev. Immunol. |
pmid:11861618
|
Roux S et al. |
RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. |
2002 |
Am. J. Clin. Pathol. |
pmid:11863217
|
Green EA et al. |
Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. |
2002 |
Immunity |
pmid:11869680
|
Holen I et al. |
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. |
2002 |
Cancer Res. |
pmid:11912131
|
Mori H et al. |
RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. |
2002 |
Histochem. Cell Biol. |
pmid:11914926
|
Takayanagi H |
[Cross-talk between immune and skeletal systems]. |
2002 |
Nippon Rinsho |
pmid:12510352
|
Shimizu-Ishiura M et al. |
Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function. |
2002 |
J Electron Microsc (Tokyo) |
pmid:12455916
|
Avbersek-Luznik I et al. |
Increased levels of osteoprotegerin in hemodialysis patients. |
2002 |
Clin. Chem. Lab. Med. |
pmid:12476941
|
Holloway WR et al. |
Leptin inhibits osteoclast generation. |
2002 |
J. Bone Miner. Res. |
pmid:11811550
|
Coen G et al. |
Serum osteoprotegerin and renal osteodystrophy. |
2002 |
Nephrol. Dial. Transplant. |
pmid:11812872
|